Ogasawara Fumiya, Ito Takehiko, Nakamura Makoto, Saeki Kyosuke, Taniguti Ayuko, Togitani Kazuto, Kojima Kensuke
Department of Hematology, Kochi Medical School, Kochi University.
Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University.
Rinsho Ketsueki. 2021;62(3):193-195. doi: 10.11406/rinketsu.62.193.
Acquired hypofibrinogenemia is observed in patients with severe liver disease, disseminated intravascular coagulation, and high-volume perioperative fluid replacement. In lymphoblastic leukemia, hypofibrinogenemia is most frequently caused by the administration of L-asparaginase. Here we report the cases of two patients with acquired hypofibrinogenemia that occurred during steroid-containing chemotherapy treatment against lymphoblastic blast crisis of chronic myeloid leukemia in the first case and acute lymphoblastic leukemia in the second case. Administration of steroids repeatedly and promptly caused hypofibrinogenemia, irrespective of the products (prednisolone, dexamethasone, or methylprednisolone) or routes (oral or intravenous) that were used. Monitoring of the fibrinogen levels, especially during the first course of steroid therapy, would be useful for early diagnosis.
在严重肝病、弥散性血管内凝血和大量围手术期液体置换的患者中可观察到获得性低纤维蛋白原血症。在淋巴细胞白血病中,低纤维蛋白原血症最常见的原因是使用L-天冬酰胺酶。在此,我们报告两例获得性低纤维蛋白原血症的病例,第一例发生在含类固醇化疗治疗慢性髓性白血病淋巴细胞母细胞危象期间,第二例发生在急性淋巴细胞白血病的含类固醇化疗治疗期间。反复且迅速地使用类固醇会导致低纤维蛋白原血症,无论使用的产品(泼尼松龙、地塞米松或甲泼尼龙)或途径(口服或静脉注射)如何。监测纤维蛋白原水平,尤其是在类固醇治疗的第一个疗程期间,将有助于早期诊断。